Medpace Holdings, Inc. $MEDP Shares Acquired by Willis Investment Counsel

Willis Investment Counsel raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.4% during the third quarter, HoldingsChannel.com reports. The fund owned 15,957 shares of the company’s stock after purchasing an additional 1,102 shares during the quarter. Willis Investment Counsel’s holdings in Medpace were worth $9,960,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Medpace during the 2nd quarter valued at approximately $1,323,047,000. Madison Asset Management LLC purchased a new stake in Medpace during the second quarter valued at approximately $128,956,000. Bank of America Corp DE bought a new stake in Medpace in the second quarter worth $116,891,000. American Capital Management Inc. bought a new stake in shares of Medpace in the 2nd quarter worth about $111,329,000. Finally, Caisse de depot et placement du Quebec purchased a new position in shares of Medpace during the second quarter valued at approximately $80,979,000. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO August Troendle sold 21,966 shares of Medpace stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the transaction, the chief executive officer owned 338,225 shares in the company, valued at $211,549,590.75. The trade was a 6.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 336,140 shares of company stock worth $208,008,328 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. BMO Capital Markets lifted their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. UBS Group began coverage on Medpace in a research report on Wednesday, September 30th. They set a “neutral” rating and a $673.00 target price on the stock. Mizuho increased their target price on Medpace from $665.00 to $700.00 and gave the company an “outperform” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, Truist Financial boosted their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $607.73.

Medpace Trading Up 1.7%

Shares of NASDAQ:MEDP traded up $10.49 on Tuesday, hitting $630.15. 128,838 shares of the company were exchanged, compared to its average volume of 325,251. The stock’s 50 day moving average price is $606.76 and its 200 day moving average price is $533.55. The firm has a market capitalization of $17.59 billion, a P/E ratio of 36.94, a price-to-earnings-growth ratio of 2.76 and a beta of 1.18. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.